(Q35848744)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

26

Kenneth C Anderson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

5

Steven R Zeldenrust

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Robert Douglas Knight

24

object named as

Robert Knight

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Paul G Richardson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Emily Blood

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Constantine S Mitsiades

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Sundar Jagannath

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Melissa Alsina

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Robert L Schlossman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

K Raman Desikan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Teru Hideshima

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Nikhil C Munshi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Kathleen Kelly-Colson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Deborah Doss

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Mary L McKenney

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Svetlana Gorelik

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Diane Warren

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Andrea Freeman

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Rebecca Rich

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Anfang Wu

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Marta Olesnyckyj

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Kenton Wride

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

William S Dalton

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Jerome Zeldis

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Edie Weller

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

English

0 references

publication date

13 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

3458-3464

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

27 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Soluble intercellular adhesion molecule-1 (sICAM-1): an overview

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

11 July 2018

Cancer statistics, 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

A phase 2 study of bortezomib in relapsed, refractory myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Potential new therapeutics for Waldenstrom's macroglobulinemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Antitumor activity of thalidomide in refractory multiple myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

The treatment of multiple myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

The evolution of thalidomide and its IMiD derivatives as anticancer agents

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895441

Randomized phase II clinical trials

14 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16840727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16840727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16840727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2006-04-015909

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16840727%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference